Report
Grifols B : Q3 EBITDA in line with our numbers. Guidance nuanced to the higher end
>Plasma collection grows at a high-single-digit pace while its unit cost keeps falling - Q3 group sales grew by +4% or +9% cc (vs +9% cc in Q2) reaching € 1.6bn, broadly in line with our numbers and the consensus. Biopharma posted a robust +8% y-o-y growth or +14% cc (vs +10% cc in Q2) to € 1.4bn driven by: i/ solid plasma collection growth (+10% in 9M vs +12% in H1), ii/ IGg demand (higher Xembify demand in the US and robust IGg demand in Europe/ROW) and price uptick...
Underlying
Grifols S.A. Pref Class B
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.